CAR-T for Primary CNS Lymphoma – pro
PCNS lymphoma was excluded for the initial trials of CAR-T. Recent evidence has shown an acceptable safety profile and some activity of anti-CD19 CAR T-cell treatment of secondary CNS lymphoma (sCNSL). Alcantara (2022) et al note: “Our results support the development of CAR T -cells in R/R PCNSL. Prospective clinical trials are needed to confirm these encouraging results. Additionally, synergic associations with immunomodulatory drugs should be tested.”
Alcantara M, Houillier C, Blonski M, Rubio MT, Willems L, Rascalou AW, Le Garff-Tavernier M, Maloum K, Bravetti C, Souchet L, Roos-Weil D, Morel V, Uzunov M, Metz C, Dhib-Charfi M, Nguyen S, Shor N, Psimaras D, Weiss N, Jacque N, Solorzano S, Gauthier N, Le Cann M, Norol F, Soussain C, Choquet S. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022 Feb 3;139(5):792-796. doi: 10.1182/blood.2021012932. PMID: 34871363; PMCID: PMC8814680.
Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783-784.
Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860-866.
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-85